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Introduction: Benzodiazepines and z-drugs (BZD/Zs) are the most 
commonly prescribed symptomatic treatment for sleep problems. 
Older persons, and more specifically the nursing home residents, 
are large consumers of these drugs (> 30% of the Belgian nursing 
home residents take BZD/Z chronically for insomnia). Chronic use 
of BZD/Z is discouraged because of the unproven long-time effective-
ness and the related side effects. The objective of this study was to 
describe sleep quality of chronic BZD/Z users and compare it with 
nonhypnotic users.
Patients (or Materials) and Methods: All mentally competent 
residents from 10 nursing homes were screened and compiled in a 
group of chronic BZDs users or in a group of nonusers, based on 
the medication chart. We collected demographic, functional, and 
medication characteristics, and global and specific sleep parameters, 
using the Pittsburgh Sleep Quality Index (PSQI). Linear regression 
was used to investigate which parameters were associated with sleep 
quality.
Results: Of the 300 residents, 178 (59%) were chronic BZD users 
and 122 nonusers. The 2 groups did not differ in demographic and 
functional characteristics (mean age, 85.5 years; range, 57−100 
years; 75% women). The users reported significantly more diffi-
culties with falling asleep, more midnight awakenings, were less 
rested in the morning, and had a worse self-perceived sleep qual-
ity compared with nonusers. Sleep duration and time to fall asleep 
did not differ. The self-perceived sleep quality was mainly deter-
mined by problems during initiation of sleep. After controlling for 
demographic, medication, and functional characteristics, BZD use 
remained strongly associated with bad sleep (r = 0.173, P = 0.003), 
and a study center effect (differences among nursing homes) was 
observed (r = 0.229, P < 0.001).
Conclusion: Our findings do not support long-term effectiveness of 
BZDs; chronic users slept worse than nonusers (even more outspo-
ken in users of long-acting BZDs). In future longitudinal compara-
tive studies of sleep quality, unexplained variability needs further 
assessment with medical, psychological, and institutional param-
eters.
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Introduction: The use of antipsychotics is highly prevalent in resi-
dential care, often used off-label for Behavioural and Psychological 
Symptoms of Dementia (BPSD). Nowadays, atypical or second-
generation antipsychotics have replaced the majority of older antip-
sychotics. We wanted to explore the indications and dosages of 
antipsychotics used by nursing home residents, focusing on atypical 
antipsychotics.
Patients (or Materials) and Methods: Medication charts of 1730 
residents from 76 nursing homes in Belgium (2006) were collected 
and analyzed, using the ATC classification. Drug name, indication, 
and daily dosage were recorded. We compared the Prescribed Daily 
Dose (PDD) with the Defined Daily Dose (DDD) for atypical antip-
sychotics based on the WHO ATC/DDD index.
Results: Nursing home residents used in 32.9% antipsychot-
ics of which 19.1% atypical and 16.1% typical antipsychotics. 
Concomitant use of ≥ 2 antipsychotic medications was found in 5% 
of the cases. Risperidone and olanzapine were the main used atypical 
antipsychotics (13.5% and 5.5%, respectively). Buterophynone deri-
vates (12.1%) were the main used typical antipsychotics, of which 
haloperidol accounted for 5%. The main indications for prescribing 
antipsychotics were agitation within dementia (57%), and psychosis 
(23%). The median PDD for risperidone was 0.5 mg (range, 0.25−9 
mg), lower than the recommended DDD (5 mg); 15 mg for aripipra-
zole, equal to the recommended DDD; 5 mg (range, 1.25–25) for 
olanzapine, lower than recommended DDD (10 mg); 100 mg (range, 
25−400 mg) for quetiapine, also lower than recommended (400 mg).
Conclusion: The DDD for antipsychotics is based on the main indi-
cation of psychosis. In Belgian nursing homes, antipsychotics are 
mainly used off-label for BPSD. The PDD of antipsychotics for nurs-
ing home residents is systematically lower than the DDD (except for 
aripiprazole), indicating that GPs do take the altered drug disposition 
of the aging body as well as the off-label indication of BPSD into 
consideration.
Disclosure of Interest: None declared.
